See It to Secure It: Why Unified Visibility Is the Backbone of Modern IT 
Where Bitcoin stands today and where the indicators point Р1, 3 and 6-month outlook 
Virtune launches Virtune Stablecoin Index ETP on Nasdaq Stockholm, Nasdaq Helsinki and Deutsche Börse Xetra Enable Announces New Products That Add to Its Rebate Management Leadership
SAN FRANCISCO–(BUSINESS WIRE)–#SPAs—Enable, the leading cloud-based software solution for B2B rebate management, announces the release…
‘Coach K’ and Morgan Stanley Executive Carla Harris to Deliver Keynote Addresses at AICPA & CIMA ENGAGE 2022
Premier event for accounting and finance professionals to be held June 6-9 in Las Vegas…
Tech Tackles Cancer 2022 Announces Tech Rockstar Lineup
Limited number of event tickets to go on sale May 26 BOSTON–(BUSINESS WIRE)–#AI–Hack/Reduce, a non-profit…
Global Procurement As A Service Market Analysis Report 2022-2030 – Growing Demand Among Enterprises to Streamline the Procurement Processes – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Procurement As A Service Market Size, Share & Trends Analysis Report by Vertical…
Insight Honored as Intel Innovation Partner of the Year for 3rd Time
Latest award recognizes Insight’s assistance in fueling Intel’s strong growth in the cloud space CHANDLER,…
Cullinan Oncology to Host Analyst and Investor Briefing at 2022 ASCO Annual Meeting
Meeting to highlight updated data from the Phase 1/2a study of CLN-081 CAMBRIDGE, Mass., May…
Galecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO Annual Meeting
Novel galectin-3-based mechanism of PD-1/PD-L1 checkpoint inhibitor resistance identified Galecto’s oral galectin-3 inhibitor candidate, GB1211,…
Rakovina Therapeutics Inc. Announces Q1 2022 Financial Results and Provides Corporate Update
VANCOUVER, British Columbia, May 26, 2022 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (TSX-V: RKV, the…
SciSparc Announces Ethics Committee Approval to Conduct a Phase IIb Trial in Tourette Syndrome
Ethics Committee approval received from the two sites that will conduct the SCI-110 trial in…
SELLAS Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in Patients with WT1+ Advanced Ovarian Cancer
– Overall Response Rate of 7.7 percent is similar to checkpoint inhibitors alone – –…
Mersana Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage…
Walden Biosciences to Participate in June Investor Conferences
Company to highlight novel multi-disciplinary approach to reverse the progression of both rare and common…
Yingli Pharma Doses First US Patient in Phase 1 Study of YL-13027 for Patients with Advanced Solid Tumors
Phase 1 study evaluates safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of YL-13027, an inhibitor…
Achieve Life Sciences Announces Participation at LD Micro Invitational Conference
SEATTLE and VANCOUVER, British Columbia, May 26, 2022 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc….
Adaptive Biotechnologies to Participate in Upcoming June Investor Conferences
SEATTLE, May 26, 2022 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a…
ACTO Bolsters Executive Management Team to Meet Significant US Commercial Growth
TORONTO, May 26, 2022 (GLOBE NEWSWIRE) — ACTO, the only complete commercial learning platform for…
CytomX Therapeutics Announces First Patient Dosed with CX-904 in Phase 1 Study in Patients with Advanced Solid Tumors
– EGFRxCD3-targeting bispecific is sixth CytomX Probody® therapeutic candidate to enter the clinic – SOUTH…
Innovative Cellular Therapeutics (ICT) Announces Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
ROCKVILLE, Md., May 26, 2022 (GLOBE NEWSWIRE) — Innovative Cellular Therapeutics, Inc. (ICT), a clinical-stage…
Caladrius Biosciences and Cend Therapeutics Announce Poster Presentation at the 2022 American Society of Clinical Oncology Annual Meeting
Poster Presentation to highlight ongoing clinical study of CEND-1 with FOLFIRINOX-based therapies in pancreatic, colorectal…
Prometheus Biosciences to Participate at the Jefferies Healthcare Conference
SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) — Prometheus Biosciences, Inc. (Nasdaq: RXDX), a clinical-stage…